Open AccessmTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28− Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection
Author(s) -
Cyd Castro-Rojas,
Alzbeta Godarova,
Tiffany Shi,
Sarah A. Hummel,
A. R. Shields,
Sylvie Tremblay,
Rita R. Alloway,
Michael B. Jordan,
E. Steve Woodle,
David Hildeman
Publication year - 2020
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002917
Subject(s) - belatacept , everolimus , medicine , immunosuppression , sirolimus , foxp3 , mtorc1 , pi3k/akt/mtor pathway , kidney transplantation , immune system , immunology , transplantation , urology , biology , apoptosis , biochemistry , kidney transplant
Renal allograft rejection is more frequent under belatacept-based, compared with tacrolimus-based, immunosuppression. We studied kidney transplant recipients experiencing rejection under belatacept-based early corticosteroid withdrawal following T-cell-depleting induction in a recent randomized trial (Belatacept-based Early Steroid Withdrawal Trial, clinicaltrials.gov NCT01729494) to determine mechanisms of rejection and treatment.